Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU

• Published in: Annals of hematology Vol. 94; no. Suppl 2; pp. 249 - 257
• Main Authors: Conti, Rena M., Padula, William V., Larson, Richard A.
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.04.2015; Springer Nature B.V
• Subjects: Animals; Antineoplastic Agents - adverse effects; Antineoplastic Agents - economics; Antineoplastic Agents - therapeutic use; Benzamides - adverse effects; Benzamides - economics; Benzamides - therapeutic use; Cost Savings; Drug Costs; Drugs, Generic - adverse effects; Drugs, Generic - economics; Drugs, Generic - therapeutic use; European Union; Fusion Proteins, bcr-abl - antagonists & inhibitors; Health Impact Assessment - methods; Hematology; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - economics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology; Medicine; Medicine & Public Health; Models, Economic; Molecular Targeted Therapy - adverse effects; Molecular Targeted Therapy - economics; Oncology; Patents as Topic; Piperazines - adverse effects; Piperazines - economics; Piperazines - therapeutic use; Practice Patterns, Physicians' - economics; Protein Kinase Inhibitors - adverse effects; Protein Kinase Inhibitors - economics; Protein Kinase Inhibitors - therapeutic use; Pyrimidines - adverse effects; Pyrimidines - economics; Pyrimidines - therapeutic use; Review Article; United States; United States; Imatinib; Health economics; Patent expiration; Chronic myeloid leukemia; Cost-effectiveness; Tyrosine kinase inhibitors; Generic entry; Cancer

Imatinib is an oral tyrosine kinase inhibitor and considered to be the most successful targeted anti-cancer agent yet developed given its substantial efficacy in treating chronic myeloid leukemia (CML) and other malignant diseases. In the USA and the European Union (EU), Novartis’ composition of mat...